NRAS and melanoma: We observed that the ATP-competitive inhibitor PHA-665752 [11] and the non-ATP-competitive, clinical phase II inhibitor ARQ197 (tivantinib) [44] elicited response in BMCs and conventional melanoma cell lines irrespective of the BRAF/NRAS mutation status.